Disrupting for Good (Not Just ‘Anti-Bad’)

It has been a very full month. I started November in Ottawa with my rare blood disorder group, hosting meetings including a two-hour roundtable discussion with patients, policymakers, physicians, and pharma reps, where we talked about the best path forward for timely and equitable access to new therapies coming to market. It also included a really hard conversation about historical and ongoing anti-Back racism in blood donation and the outsized impact that is having on the Sickle Cell community. 

Read More